Introduction
============

Diabetes is a chronic disease due to impaired glucose homeostasis, that manifests as hyperglycemia. According to the IDF diabetes atlas released by the International Diabetes Federation (IDF) in 2017, there are 425 million individuals with diabetes worldwide and this is estimated to grow to 629 million by 2045.[@b1-dddt-12-1581] The onset of type 2 diabetes is due to the decrease of insulin secretion, the defect of the effect of insulin as well as insulin resistance of the target tissue (fat, muscle and liver).[@b2-dddt-12-1581] Skeletal muscles play an important role in whole body glucose homeostasis. Glucose uptake is mainly mediated by transmembrane protein glucose transporter 4 (GLUT4) in skeletal muscle cells. The amount of glucose uptake is determined by the number of GLUT4 on muscle cell membrane.[@b3-dddt-12-1581],[@b4-dddt-12-1581] The Chinese herb, *Potentilla chinensis*, has been shown to reduce blood glucose levels of diabetic mice, and tiliroside is the main effective component.[@b5-dddt-12-1581],[@b6-dddt-12-1581] We previously synthesized a series of derivatives, which significantly enhanced glucose uptake in skeletal muscle cells and glucose consumption in insulin resistant (IR) HepG2 liver cells.[@b7-dddt-12-1581]--[@b9-dddt-12-1581] However, it is important to determine a compound's mechanism of action to evaluate its potential usefulness in drug discovery. This study aims to find effective flavonoid derivatives that regulate glucose uptake and illustrate the underlying mechanism in muscle cells. To focus on the role of GLUT4, we used muscle cell lines stably expressing GLUT4*myc* with an exofacial *myc* epitope. The effect of these compounds on GLUT4 was investigated by detection of cell surface GLUT4*myc* levels, via its *myc* epitope, by the enzyme-linked immunosorbent assay (ELISA).

Materials and methods
=====================

Reagents
--------

Horseradish peroxidase (HRP)-bound goat anti-rabbit IgG antibody and donkey anti-mouse IgM antibody were from Jackson Immuno Research Laboratories (West Grove, PA, USA). Minimum Essential Medium Eagle alpha (α-MEM) from HyClone (Beijing, China). Fetal bovine serum (FBS) and trypsin-EDTA were purchased from BioInd (Beit HaEmek, Israel). Immobilon Western Chemiluminescent HRP Substrate was purchased from Millipore (Billerica, MA, USA). o-Phenylenediamine dihydrochloride (OPD), DMSO, orthovanadate, protease inhibitor cocktail, and other chemicals were from Sigma-Aldrich Co. (St Louis, MO, USA). Polyclonal antibodies to p-AS160 (Thr642) antibody were from Cell Signaling Technology (Danvers, MA, USA). Monoclonal IgM to-actinin-1 (clone BM-75.2) was from Sigma-Aldrich Co. β-actin was obtained from Abmart (Shanghai, China). The antibodies to GLUT4, L6-GLUT4*myc* and L6-AS160 4A-GLUT4*myc* cell lines were kindly provided by Dr Amira Klip at The Hospital for Sick Children (Toronto, Canada). This research had approval from The Medical Ethics Committee of Tianjin Medical University.

Synthesis of tiliroside derivatives
-----------------------------------

The tiliroside derivatives were synthesized via three steps including Classin--Schmitt reaction, α-bromination of the unsaturated ketone and etherification reaction, as previously described.[@b8-dddt-12-1581] Briefly, compounds D1--D22 were synthesized through three steps. The first step was a Classin--Schimitt reaction from the substituted benzaldehyde to the α, β-unsaturated keto. Then the hydrogen atom in this keto was substituted by a bromine atom. Finally, the compounds D1--D22 were prepared by the etherification reaction with kaempferol.[@b8-dddt-12-1581] The structures of compounds D1--D22 were determined by ^1^H, ^13^C NMR and 2D NMR spectral data analysis, including correlation spectroscopy (COSY), heteronuclear single quantum coherence (HSQC), heteronuclear multiple bond correlation (HMBC), and rotating-frame nuclear Overhauser effect spectroscopy (ROESY).

Cell culture and treatment
--------------------------

Rat L6-GLUT4*myc* and L6-AS160 4A-GLUT4*myc* cell lines were as described.[@b10-dddt-12-1581] Briefly, Akt substrate of 160 kDa (AS160) with 4-point mutations (S318A, S588A, T642A, S751A) which could not be phosphorylated was overexpressed into L6-GLUT4*myc* cells. Myoblasts were cultured and differentiated into myotubes as described.[@b8-dddt-12-1581] Cells were depleted of serum for 4 h prior to all assays. Pre-treatment with Compound C and stimuli were timed so their completion would coincide with the end of the serum deletion period of 4 h. Compound C was administered 30 min prior to treatment with the derivatives. Insulin (100 nM) and 1 mM metformin were used to treat the cells for 30 min.

Measurement of cell surface GLUT4*myc* density
----------------------------------------------

GLUT4*myc* levels at the intact cell surface were measured by ELISA as described.[@b11-dddt-12-1581] Briefly, cells were treated as required and fixed with paraformaldehyde (PFA) prior to quenching with 0.1 M glycine in PBS. Cells were incubated with polyclonal anti-myc antibody in 5% v/v goat serum in PBS, then were incubated with HRP-bound secondary antibody. Cells were incubated with OPD for several minutes and the reaction was stopped with 3M HCl. Supernatant absorbance was measured at 492 nm to obtain readings in the linear range. Background absorbance obtained from cells not incubated with anti-myc antibody was subtracted from all values.

Cell lysates and immunoblotting
-------------------------------

Myotubes were lysed on ice with 100 µL of radioimmunopre-cipitation assay (RIPA) buffer and processed as described.[@b12-dddt-12-1581] Samples were resolved on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), transferred to polyvinylidene difluoride (PVDF) membranes (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Protein phosphorylation and expression were detected with specific antibodies. The protein bands were densitometric quantification by using National Institutes of Health (NIH) ImageJ software.

Statistical analysis
--------------------

Results were presented as mean±standard error (SE). Statistical analyses were carried out using Prism 6.0 software (GraphPad Software, Inc., La Jolla, CA, USA). Student's *t*-test was used to compare pairs of data. Data sets with three or more groups were compared using one-way or two-way analysis of variance with Tukey's post hoc analysis. Results were considered to be statistically significant if *p*\<0.05.

Results
=======

Tiliroside derivatives synthesis and effects on GLUT4 translocation
-------------------------------------------------------------------

Tiliroside ([Figure 1A](#f1-dddt-12-1581){ref-type="fig"}) was previously isolated from Chinese herb *P. chinensis*. Twenty-two tiliroside derivatives were synthesized by modifying the structure of tiliroside as shown in [Figure 1B](#f1-dddt-12-1581){ref-type="fig"}.

Treatment with 10 µg/mL of tiliroside derivatives for 24 h significantly increased surface GLUT4*myc* levels in L6-GLUT4*myc* myotubes. The fold increases above basal levels of D1, D8, D9, D11, D14, D16 and D17--D19 were 3.6±0.3, 3.6±0.2, 2.8±0.4, 3.1±0.3, 3.9±0.3, 4.0±0.5, 2.8±0.4, 3.3±0.6 and 4.4±0.6, respectively ([Table 1](#t1-dddt-12-1581){ref-type="table"}). Among these derivatives, D1, D8 and D18 had the strongest effects compared to other derivatives. In addition, GLUT4*myc* translocation in L6-GLUT4*myc* myotubes responded to derivatives D1, D8 and D18 in a dose- and time-dependent manner ([Figure 2A and B](#f2-dddt-12-1581){ref-type="fig"}). The maximal GLUT4*myc* translocation stimulated by 10 µg/mL derivatives D1, D8 and D18 for 24 h were 3.3±0.3, 3.7±0.2 and 3.2±0.2, respectively (\*\*\**p*\<0.001; [Figure 2](#f2-dddt-12-1581){ref-type="fig"}).

The role of AMPK in the effects of tiliroside derivatives on GLUT4
------------------------------------------------------------------

In order to illustrate the mechanism of the derivatives- regulated GLUT4*myc* translocation, we detected two well-known signaling pathways which mediated insulin- or contraction-stimulated GLUT4*myc* translocation, respectively. The results showed that insulin and derivatives D1, D8 and D18 significantly stimulated GLUT4*myc* translocation 2-fold more than basal untreated cells ([Figure 3A](#f3-dddt-12-1581){ref-type="fig"}). Moreover, the effects of derivatives D1, D8 and D18 on GLUT4*myc* translocation were additive with insulin (*p*\<0.01, [Figure 3A](#f3-dddt-12-1581){ref-type="fig"}). Importantly, they did not lead to phosphorylation of protein kinase B (Akt) ([Figure 3A](#f3-dddt-12-1581){ref-type="fig"}). These data suggested that the regulatory mechanism of these derivatives on GLUT4 was different with insulin. We next detected the phosphorylation of adenosine monophosphate-activated protein kinase (AMPK). The results showed that derivatives D1, D8 and D18 increased the phosphorylation of AMPK (pAMPK) and its downstream substrate, acetyl-CoA carboxylase (pACC) to a similar degree as metformin ([Figure 3B](#f3-dddt-12-1581){ref-type="fig"}). Derivatives D1, D8 and D18 significantly increased pAMPK by 2.2±0.2, 1.9±0.2 and 1.8±0.3-fold, respectively. The fold increases of pACC by derivatives D1, D8 and D18 were 1.7±0.3, 1.7±0.1 and 1.7±0.3-fold, respectively (*p*\<0.05, *p*\<0.01 vs basal untreated, respectively). These results suggested that AMPK was activated by these derivatives. We next used the AMPK inhibitor, Compound C, to test the role of AMPK in the derivatives-regulated GLUT4*myc* translocation. [Figure 3C](#f3-dddt-12-1581){ref-type="fig"} showed that Compound C completely reduced the ability of these derivatives to increase cell surface GLUT4*myc*, implying that AMPK mediated the effect of these derivatives on GLUT4 translocation. As expected, the derivatives reversed insulin resistance induced by high glucose and high insulin ([Figure 3D](#f3-dddt-12-1581){ref-type="fig"}).

The role of AS160 in the effects of tiliroside derivatives on GLUT4
-------------------------------------------------------------------

We previously showed that AS160 lies downstream of AMPK to mediate contraction-stimulated GLUT4 translocation in skeletal muscle cells.[@b10-dddt-12-1581]--[@b12-dddt-12-1581] AS160 is known as a Rab-GTPase activating protein (GAP). In basal conditions, AS160 has Rab-GAP activity that maintains the Rab substrates in the inactive GDP-bound form, leading to intracellular GLUT4 retention.[@b13-dddt-12-1581] When phosphorylated by AMPK, its Rab-GAP activity becomes inactivated and the inhibition on its Rab substrates is removed; in turn, the activated Rabs regulate GLUT4 storage vesicle mobilization to the cell surface.[@b14-dddt-12-1581],[@b15-dddt-12-1581] Here, we found that AS160 responded to derivative D8 and became phosphorylated in L6-GLUT4*myc* cells ([Figure 4A](#f4-dddt-12-1581){ref-type="fig"}). To further explore the requirement for AS160 in D8-promoted GLUT4*myc* translocation, we used L6-GLUT4*myc* cells overexpressing non-phosphorylatable AS160 4A (L6-AS160 4A-GLUT4*myc*). D8 could not phosphorylate AS160 in L6-AS160 4A-GLUT4*myc* myotubes ([Figure 4A](#f4-dddt-12-1581){ref-type="fig"}). Accordingly, D8-stimulated GLUT4*myc* translocation was reduced in L6-AS160 4A-GLUT4*myc* cells (2.7±0.3-fold in L6-GLUT4*myc* myotubes vs 1.7±0.1-fold in L6-AS160 4A-GLUT4*myc* myotubes, *p*\<0.01, [Figure 4B](#f4-dddt-12-1581){ref-type="fig"}). These data indicated that D8-enhanced GLUT4*myc* translocation is partly mediated by AS160.

Discussion
==========

Skeletal muscles take up approximately 80% of dietary glucose following a meal. This plays an important role in insulin resistance and type 2 diabetes, which are conditions in which insulin-regulated signal and glucose uptake are impaired. However, other than insulin there are no clinically used treatments that target muscle cell glucose utilization. Exercise/contraction can also enhance glucose uptake via GLUT4 by signaling pathways different to that of insulin. A drug which activates insulin or contraction signaling pathways may potentially relieve insulin resistance. Tiliroside in the Chinese herb *P. chinensis* can reduce blood glucose level of diabetic mice.[@b5-dddt-12-1581],[@b6-dddt-12-1581] We previously synthesized a small series of tiliroside derivatives and found they promoted GLUT4 translocation to the cell surface.[@b9-dddt-12-1581] We revealed 3-O-\[(E)-4-(4-cyanophenyl)-2-oxobut-3-en-1-yl\] kaempferol (D3) was the most active compound to increase surface GLUT4*myc* levels in L6-GLUT4*myc* and C2C12-GLUT4*myc* myotubes.[@b9-dddt-12-1581] In order to find more effective compounds to regulate glucose metabolism, we synthesized another set of 3-substituted derivatives of kaempferol with different modifications. In the current study, we investigated their effects on GLUT4 translocation and related signaling pathways.

Upon challenge with insulin or contraction, GLUT4 translocates to and inserts into the cell surface of skeletal muscle myofibers from intracellular storage vesicles to begin transporting glucose into the cells. In this study, overexpressing GLUT4 with a *myc* epitope in the L6 muscle cell line allows us to score cell surface GLUT4 content which correlates with glucose uptake. Specifically, when GLUT4*myc* translocates to the cell surface, the *myc* epitope is exposed to outside of the cell and this can be detected by ELISA, in the intact cells. By measuring GLUT4*myc* translocation to the cell surface, we focus on GLUT4 without the involvement of other GLUTs, like GLUT1 and GLUT3.

We found that the newly synthesized derivatives more effectively enhance GLUT4*myc* translocation than our previous reported tiliroside derivatives. We further found that derivatives D1, D8 and D18 stimulated GLUT4*myc* translocation in a time- and dose-dependent manner. Insulin and contraction are two main stimuli to enhance glucose metabolism in muscle, but they utilize different proximal signaling mechanisms and together, they can have additive effects on the stimulation of glucose uptake. We found the effects of D1, D8 and D18 derivatives tiliroside on GLUT4*myc* translocation were additive with acute insulin stimulation and had no effect on the key insulin signal molecule, Akt.[@b16-dddt-12-1581] AMPK is the key signal molecule stimulated by muscle contraction. GLUT4 translocation is stimulated by AMPK activition.[@b10-dddt-12-1581] To examine the contribution of AMPK to the gain in surface GLUT4 in derivatives-stimulated myotubes, we inhibited AMPK with its inhibitor, Compound C. We found Compound C completely reduced GLUT4*myc* translocation stimulated by tiliroside derivatives. This demonstrated that AMPK mediates the effect of tiliroside derivatives on GLUT4 translocation.

Downstream of AMPK, contraction induces phosphorylation of the Rab-GAPs AS160 and TBC1 domain family member 1 (TBC1D1), to regulate insulin- or contraction-stimulated GLUT4 vesicle traffic.[@b10-dddt-12-1581],[@b17-dddt-12-1581] When the key regulatory serine or threonine residues of AS160 and TBC1D1 are phosphorylated by insulin or contraction, their Rab-GAP activity is inhibited and their target Rabs become GTP-loaded to promote GLUT4 translocation.[@b17-dddt-12-1581] We found Compound C inhibited the D8-mediated phosphorylation of AS160 Thr642 (data not shown). This suggests that AS160 may lie downstream of AMPK to mediate derivative D8-regulated GLUT4 traffic. In adipocytes and muscle cells, overexpression of the AS160 mutant AS160 4A, which cannot become phosphorylated, acts in a constitutively active, dominant manner, preventing the phosphorylation of the endogenous AS160 and hence signal transmission in response to insulin.[@b18-dddt-12-1581] A key finding of the present study is that stable expression of the constitutively active AS160 4A mutant in L6-GLUT4*myc* myotubes effectively prevented the induction of GLUT4*myc* translocation by the tiliroside derivative, D8. This suggested that AS160 is required for the effect of derivative D8 on GLUT4 translocation. However, the AS160 4A mutant only partly inhibited derivative D8-induced GLUT4*myc* translocation. It is likely that other signaling molecules such as TBC1D1 may be also involved in this mechanism. We also measured the effect of tiliroside derivatives on the activation of Akt, the kinase utilized by insulin to regulate AS160 phosphorylation and GLUT4 translocation. In fact, D1, D8 or D18 tended to reduce the basal levels of phospho-Akt ([Figure 3A](#f3-dddt-12-1581){ref-type="fig"}). This mechanism requires further investigation, but it could involve down-regulation of mTOR activity through lowering of phosphatidic acid levels by activated AMPK, as recently illustrated for AICAR.[@b19-dddt-12-1581],[@b20-dddt-12-1581] Together, our result demonstrates that phosphorylation/inactivation of the Rab-GAPs is required for signal transmission toward GLUT4 translocation upon derivatives D8 treatment.

In the present study, we also report that derivative D8 could reverse muscle cell insulin resistance-induced by chronic exposure to high glucose and high insulin. This further suggests that derivative D8 stimulated GLUT4 translocation by a different mechanism compared to insulin.

Conclusion
==========

Tiliroside derivatives promote GLUT4 translocation in muscle cells by a mechanism different from insulin. AMPK and AS160 are required for this effect and tiliroside-derivative D8 could reverse insulin resistance. Importantly, contraction-stimulated glucose uptake is not impaired in insulin-resistant states such as obesity and type 2 diabetes.[@b21-dddt-12-1581] Thus, our study may contribute to the drug development for treatments of type 2 diabetes.
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![Chemical structures of tiliroside (**A**) and 22 tiliroside derivatives (**B**).](dddt-12-1581Fig1){#f1-dddt-12-1581}

![Effects of derivatives D1, D8, and D18 on GLUT4*myc* translocation in L6-GLUT4*myc* myotubes. Dose-dependent (**A**) and time-dependent (**B**) measurements of GLUT4*myc* translocation following tiliroside derivative treatment. Myotubes were serum starved for 4 h followed by incubation with derivative D1, D8, or D18 for indicated dose and time. Cell surface GLUT4*myc* level was measured as detailed in the "Materials and methods" section. Results are the mean±SE of 4 independent experiments in triplicate.\
**Note:** \**p*\<0.05, \*\**p*\<0.01, \*\*\**p*\<0.001 vs basal (untreated).\
**Abbreviation:** SE, standard error.](dddt-12-1581Fig2){#f2-dddt-12-1581}

![Additivity of the derivatives with insulin and the role of AMPK in the effects of the derivatives on GLUT4 in L6-GLUT4*myc* myotubes. Myotubes were serum starved for 4 h followed by the indicated treatment with D1, D8 or D18 for 24 h or with insulin (Ins), metformin (Met) or Compound C, as detailed in the "Material and methods" section. The role of insulin in the derivatives-regulated cell surface GLUT4*myc* levels and immunoblotted for Akt and pAkt (**A**). Cell lysates were immunoblotted for AMPK, pAMPK, pACC and GLUT4 (**B**). The role of Compound C, which is the inhibitor of AMPK, in the derivatives-regulated cell surface GLUT4*myc* levels (**C**). The role of insulin in the derivatives D8 regulated cell surface GLUT4*myc* levels. Insulin resistance was induced by 25 mM glucose and 100 nM insulin for 24 h (**D**). Then the cells were treated with insulin or/and derivative D8 as A. Results are the mean±SE of 4 independent experiments. \**p*\<0.05, \*\**p*\<0.01, \*\*\**p*\<0.001 vs basal (untreated) or as indicated.\
**Abbreviations:** DMSO, dimethyl sulfoxide; SE, standard error; Bas, untreated basal.](dddt-12-1581Fig3){#f3-dddt-12-1581}

![Effects of derivatives on AS160 phosphorylation and GLUT4*myc* translocation in L6-GLUT4*myc* myotubes or L6-GLUT4*myc* myotubes stably expressing AS160-4A. Myotubes were treated with 1 µg/mL D8 for 24 h, or with 100 nM insulin for 10 min, respectively. (**A**) Immunoblots of pAMPK, pAS160, pAkt and actinin-1 (as loading control) in cell lysates. (**B**) Cell surface GLUT4*myc* levels. Results are the mean±SE of 4 independent experiments.\
**Note:** \**p*\<0.05, \*\**p*\<0.01, \*\*\**p*\<0.001 vs each basal (untreated) or as indicated.\
**Abbreviations:** Ins, insulin; SE, standard error; Bas, untreated basal.](dddt-12-1581Fig4){#f4-dddt-12-1581}

###### 

Effects of tiliroside derivatives on GLUT4*myc* translocation in L6-GLUT4*myc* myotubes (fold above untreated basal, mean ± SE)

  Derivatives   Fold                                                         Derivatives   Fold                                                         Derivatives   Fold
  ------------- ------------------------------------------------------------ ------------- ------------------------------------------------------------ ------------- ----------------------------------------------------------
  Insulin       2.7 ± 0.2[\*\*](#tfn2-dddt-12-1581){ref-type="table-fn"}     D7            1.3 ± 0.2[\*](#tfn1-dddt-12-1581){ref-type="table-fn"}       D15           1.6 ± 0.2[\*](#tfn1-dddt-12-1581){ref-type="table-fn"}
  Metformin     3.1 ± 0.2[\*\*](#tfn2-dddt-12-1581){ref-type="table-fn"}     D8            3.6 ± 0.2[\*\*\*](#tfn3-dddt-12-1581){ref-type="table-fn"}   D16           4.0 ± 0.5[\*\*](#tfn2-dddt-12-1581){ref-type="table-fn"}
  D1            3.6 ± 0.3[\*\*\*](#tfn3-dddt-12-1581){ref-type="table-fn"}   D9            2.8 ± 0.4[\*\*](#tfn2-dddt-12-1581){ref-type="table-fn"}     D17           2.8 ± 0.4[\*\*](#tfn2-dddt-12-1581){ref-type="table-fn"}
  D2            1.9 ± 0.5[\*\*](#tfn2-dddt-12-1581){ref-type="table-fn"}     D10           2.6 ± 0.2[\*\*](#tfn2-dddt-12-1581){ref-type="table-fn"}     D18           3.3 ± 0.6[\*\*](#tfn2-dddt-12-1581){ref-type="table-fn"}
  D3            2.0 ± 0.3[\*\*](#tfn2-dddt-12-1581){ref-type="table-fn"}     D11           3.1 ± 0.3[\*\*](#tfn2-dddt-12-1581){ref-type="table-fn"}     D19           4.4 ± 0.6[\*\*](#tfn2-dddt-12-1581){ref-type="table-fn"}
  D4            1.9 ± 0.3[\*\*](#tfn2-dddt-12-1581){ref-type="table-fn"}     D12           2.4 ± 0.6[\*](#tfn1-dddt-12-1581){ref-type="table-fn"}       D20           1.3 ± 0.2[\*](#tfn1-dddt-12-1581){ref-type="table-fn"}
  D5            2.0 ± 0.5[\*](#tfn1-dddt-12-1581){ref-type="table-fn"}       D13           1.5 ± 0.3[\*](#tfn1-dddt-12-1581){ref-type="table-fn"}       D21           1.5 ± 0.2[\*](#tfn1-dddt-12-1581){ref-type="table-fn"}
  D6            2.0 ± 0.6[\*](#tfn1-dddt-12-1581){ref-type="table-fn"}       D14           3.9 ± 0.3[\*\*\*](#tfn3-dddt-12-1581){ref-type="table-fn"}   D22           2.6 ± 0.6[\*](#tfn1-dddt-12-1581){ref-type="table-fn"}

**Note:**

*p*\<0.05,

*p*\<0.01,

*p*\<0.001 vs untreated basal.

**Abbreviation:** SE, standard error.
